Companies › Eli Lilly › Cash and equivalents
Eli Lilly cash and cash equivalents, 2008–2025
Eli Lilly reported cash and cash equivalents of $7.27 billion at the end of the fiscal year ended Dec. 31, 2025, up 122.4% from $3.27 billion the year before, according to its Form 10-K.
Fiscal years labeled by the year in which they ended. Bars drawn from the table below.
Eli Lilly cash and cash equivalents by fiscal year
| Fiscal year ended | Cash and equivalents | Change | Filing |
|---|---|---|---|
| Dec. 31, 2025 | $7.27B | +122.4% | 10-K (2026) ↗ |
| Dec. 31, 2024 | $3.27B | +15.9% | 10-K (2026) ↗ |
| Dec. 31, 2023 | $2.82B | +36.4% | 10-K (2025) ↗ |
| Dec. 31, 2022 | $2.07B | −45.9% | 10-K (2024) ↗ |
| Dec. 31, 2021 | $3.82B | +4.4% | 10-K (2023) ↗ |
| Dec. 31, 2020 | $3.66B | +56.5% | 10-K (2022) ↗ |
| Dec. 31, 2019 | $2.34B | −68.1% | 10-K (2021) ↗ |
| Dec. 31, 2018 | $7.32B | +12.0% | 10-K (2020) ↗ |
| Dec. 31, 2017 | $6.54B | +42.6% | 10-K (2019) ↗ |
| Dec. 31, 2016 | $4.58B | +25.0% | 10-K (2019) ↗ |
| Dec. 31, 2015 | $3.67B | −5.3% | 10-K (2019) ↗ |
| Dec. 31, 2014 | $3.87B | +1.1% | 10-K (2018) ↗ |
| Dec. 31, 2013 | $3.83B | −4.7% | 10-K (2017) ↗ |
| Dec. 31, 2012 | $4.02B | −32.1% | 10-K (2016) ↗ |
| Dec. 31, 2011 | $5.92B | −1.2% | 10-K (2015) ↗ |
| Dec. 31, 2010 | $5.99B | +34.3% | 10-K (2014) ↗ |
| Dec. 31, 2009 | $4.46B | −18.8% | 10-K (2013) ↗ |
| Dec. 31, 2008 | $5.50B | — | 10-K (2012) ↗ |
Other Eli Lilly financials
RevenueNet incomeDiluted EPSR&D expenseOperating cash flowDividends per shareDiluted sharesTotal assetsStockholders' equity Quarterly results and next earnings date Eli Lilly company hub
FAQ
Q What was Eli Lilly's cash and cash equivalents in its latest fiscal year?
A Eli Lilly reported cash and cash equivalents of $7.27 billion at the end of the fiscal year ended Dec. 31, 2025, up 122.4% from $3.27 billion the year before, according to its Form 10-K.
Q What is Eli Lilly's highest annual cash and cash equivalents on record here?
A $7.32 billion, in the fiscal year ended Dec. 31, 2018, among the fiscal years 2008–2025 reported in its 10-K XBRL data.
Q Where does this cash and cash equivalents data come from?
A From Eli Lilly's annual reports on Form 10-K, as tagged in XBRL and published by the SEC (company facts). Cash and cash equivalents on the balance sheet at fiscal year-end (excluding marketable securities).
Source: Eli Lilly's annual reports on Form 10-K via SEC XBRL company facts, updated Oct. 15, 2026. Cash and cash equivalents on the balance sheet at fiscal year-end (excluding marketable securities). For each year the most recent 10-K that reports it is used, so a figure a company later restated shows the restated value; the filing link shows which report it came from. Change is our arithmetic. Financial data, not investment advice.